| case report | Q2782326 |
| scholarly article | Q13442814 |
| P2093 | author name string | Jian Wang | |
| Lin Yang | |||
| Tengfei Zhang | |||
| Jing Liu | |||
| Lu Zhang | |||
| Peikun Ding | |||
| Guanggui Ding | |||
| Yuxin Wen | |||
| P2860 | cites work | Potential of afatinib in the treatment of patients with HER2-positive breast cancer | Q26999050 |
| Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker | Q27681964 | ||
| Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors | Q27853154 | ||
| HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib. | Q27853242 | ||
| Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives | Q28289431 | ||
| Diverse somatic mutation patterns and pathway alterations in human cancers | Q29619825 | ||
| Treatment of metastatic extramammary Paget's disease associated with adnexal adenocarcinoma, with anti-HER2 drugs based on genomic alteration ERBB2 S310F | Q34127918 | ||
| The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis | Q34493341 | ||
| Targeted therapy in NSCLC driven by HER2 insertions | Q35200528 | ||
| Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. | Q36221780 | ||
| HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers. | Q36423790 | ||
| Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment | Q36785721 | ||
| EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. | Q37021792 | ||
| Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. | Q37398636 | ||
| Afatinib treatment in advanced non-small cell lung cancer | Q37645209 | ||
| Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer | Q38179266 | ||
| Afatinib for the treatment of advanced non-small-cell lung cancer. | Q38197278 | ||
| Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity | Q38272701 | ||
| Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. | Q40449400 | ||
| HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations. | Q54336136 | ||
| A Rare Case of S310F Somatic ERBB2 Mutation in a HER2-Nonamplified Breast Cancer. | Q55015674 | ||
| Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains | Q82448154 | ||
| P433 | issue | 6 | |
| P921 | main subject | adenocarcinoma | Q356033 |
| P304 | page(s) | 450-453 | |
| P577 | publication date | 2018-04-12 | |
| P1433 | published in | Cancer Biology and Therapy | Q2544651 |
| P1476 | title | Efficacy generated by afatinib in a lung adenocarcinoma patient harboring HER2 S310Y mutation | |
| P478 | volume | 19 |
| Q58092149 | Afatinib as first-line treatment for advanced lung adenocarcinoma patients harboring HER2 mutation: A case report and review of the literature |
| Q60307729 | Clinical benefit from afatinib in an advanced squamous cell lung carcinoma patient harboring S310Y mutation: a case report |
| Q92068530 | Response to Afatinib in a Patient with Non-Small Cell Lung Cancer Harboring HER2 R896G Mutation: A Case Report |
| Q91637215 | Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer |
| Q90206293 | Triple Trouble: A Case of Multiple Resistance Mechanisms after First Generation EGFR-TKI in NSCLC |
Search more.